AbbVie Inc
General ticker "ABBV" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $312.5B
AbbVie Inc follows the US Stock Market performance with the rate: 32.0%.
Estimated limits based on current volatility of 1.2%: low 175.26$, high 179.35$
Factors to consider:
- Company included in S&P500 list
- Company pays dividends: last record date 2024-10-15, amount 1.55$ (Y3.44%)
- US accounted for 77.1% of revenue in the fiscal year ended 2023-12-31
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2023-12-31 to 2025-12-30
- 2023-12-31 to 2024-12-30 estimated range: [115.14$, 173.11$]
- 2024-12-30 to 2025-12-30 estimated range: [127.33$, 189.29$]
Financial Metrics affecting the ABBV estimates:
- Positive: Non-GAAP EPS, $ of 11.11 > 2.29
- Positive: Operating profit margin, % of 23.41 > 19.51
- Positive: 7.18 < Operating cash flow per share per price, % of 8.69
- Negative: -0.39 < Industry inventory ratio change (median), % of 0
- Positive: -3.48 < Investing cash flow per share, $ of -1.14
Short-term ABBV quotes
Long-term ABBV plot with estimates
Financial data
| YTD | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|
| Operating Revenue | $55,765.00MM | $57,998.00MM | $54,497.00MM |
| Operating Expenses | $37,841.00MM | $39,881.00MM | $41,740.00MM |
| Operating Income | $17,924.00MM | $18,117.00MM | $12,757.00MM |
| Non-Operating Income | $-4,935.00MM | $-4,640.00MM | $-6,507.00MM |
| Interest Expense | $2,423.00MM | $2,230.00MM | $2,224.00MM |
| R&D Expense | $7,084.00MM | $6,510.00MM | $8,453.00MM |
| Income(Loss) | $12,989.00MM | $13,477.00MM | $6,250.00MM |
| Taxes | $1,440.00MM | $1,632.00MM | $1,377.00MM |
| Profit(Loss) | $11,549.00MM | $11,845.00MM | $4,873.00MM |
| Stockholders Equity | $15,408.00MM | $17,254.00MM | $10,360.00MM |
| Inventory | $3,128.00MM | $3,579.00MM | $4,099.00MM |
| Assets | $146,529.00MM | $138,805.00MM | $134,711.00MM |
| Operating Cash Flow | $22,777.00MM | $24,943.00MM | $22,839.00MM |
| Capital expenditure | $787.00MM | $695.00MM | $777.00MM |
| Investing Cash Flow | $-2,344.00MM | $-623.00MM | $-2,009.00MM |
| Financing Cash Flow | $-19,039.00MM | $-24,803.00MM | $-17,222.00MM |
| Earnings Per Share* | $6.48 | $6.65 | $2.73 |
* EPS are Split Adjusted, recent splits may be reflected with a delay.